



## ASX ANNOUNCEMENT

8 February 2024

### SUCCESSFUL PLACEMENT OF RIGHTS ISSUE SHORTFALL

**Melbourne, Australia – Opyl Limited (ASX:OPL) (the “Company”)** is pleased to announce that the company has successfully completed a placement of all 4,666,666 partial underwriting shares and all 24,873,344 shortfall shares at an issue price of \$0.03 per share, raising an additional \$886,200 (before costs) under the shortfall facility of the rights issue, which closed on 15 January 2024.

The shortfall placement together with the support of the rights issue has raised approximately \$1,433,358 before costs through the issue of 47,778,604 new fully paid ordinary shares. The shares on issue at completion is as follows:

Description	# of shares
Total shares on issue at time of Entitlement Offer	119,446,545
Shares applied for by eligible shareholders under the Entitlement Offer	18,238,594
Shortfall under the Top-Up Offer	29,540,010
Total shares issued	47,778,604
Total shares on issue on completion of Entitlement Offer	167,225,149

The shares to be issued under the shortfall placement will rank equally with existing fully paid ordinary shares in the company.

Funds raised from both the placement (announced on 12 December 2023) and the non-renounceable rights issue will be applied to the following initiatives critical to unlocking flagship revenue for TrialKey and enhancing scalability of the platform:

1. Sales, marketing and support initiatives for TrialKey's in-progress commercialisation strategy;
2. Targeted technology development for the TrialKey platform, focused on improving infrastructure scalability and UX/UI; and
3. Working capital.

The Board and management team would like to thank both existing and new shareholders for their participation and support shown through the capital raisings.

The Board has authorised this announcement for release to the ASX.

**-ENDS-**

**For investor enquiries:**

Stefan Jacobs  
Vesparum Capital  
Phone: +61 3 8582 4800  
Email: [opyl@vesparum.com](mailto:opyl@vesparum.com)

**For general enquiries:**

Email: [info@opyl.ai](mailto:info@opyl.ai)  
Website: [www.opyl.ai](http://www.opyl.ai)

**About Opyl Limited**

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials and predicting outcomes. Our platforms provide targeted insights that make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money. Our key offering for biopharma, medtech, government and healthcare organisations are Opin.ai (clinical trial recruitment solutions) and Trial Key (clinical trial predictive analytics and protocol design).